IDEAS home Printed from
   My bibliography  Save this paper

Corporate Governance and Firm Strategy in the Pharmaceutical Industry


  • Steven Casper
  • Catherine Matraves


Using the case of the pharmaceutical industry, this paper assesses how the leading German and UK firms are adapting to changes in their competitive environment, at both the national and international level. We attempt to link how firms create governance structures (management decision-making, the organisation of the R&D process, etc.), and the national system of innovation, impact the innovation strategies adopted in leading German and UK firms. Our results show that first, the firm competencies created in order to compete globally may still originate within national economies, in part because the generation of R&D remains relatively national. Second, towards the end of the 1970s, the scientific basis in the pharmaceutical industry began to change rapidly. The evidence presented shows that UK firms rapidly developed new competencies in biotechnology and other research areas in response to the structural changes. However, German firms tended, until very recently, to maintain and in some cases strengthen competencies in traditional research methods based on organic chemistry. ZUSAMMENFASSUNG - (Corporate Governance und Unternehmensstrategie in der pharmazeutischen Industrie) Am Beispiel der pharmazeutischen Industrie wird in diesem Beitrag aufgezeigt, wie führende deutsche und britische Firmen sich an Änderungen in ihrer Unternehmensumwelt anpassen, sowohl der nationalen wie auch der internationalen Umwelt. Es wird gezeigt, wie die Unternehmen Governance-Strukturen (Managemententscheidungen, die Organisation von FuE-Prozessen etc.) schaffen und wie nationale Innovationssysteme die Innovationsstrategien beeinflussen, die von führenden deutschen und britischen Firmen verfolgt werden. Erstens gelangt die Studie zu dem Ergebnis, daß die Kompetenz der Unternehmen so ausgerichtet wurde, daß sie für den globalen Wettbewerb fit sind, aber ihre Wurzeln dennoch innerhalb der nationalen Volkswirtschaften behalten, teilweise deshalb, weil FuE verhältnismäßig national fundiert ist. Zweitens begann zum Ende der siebziger Jahre eine dramatische Änderung in der wissenschaftlichen Basis der pharmazeutischen Industrie. Diese Evidenz zeigt, daß britische Firmen rasch neue Kompetenz in Biotechnologie und anderen Forschungsbereichen entwickelten, um auf die Änderungen zu reagieren. Deutsche Unternehmen tendierten jedoch noch bis vor kurzem dazu, ihre bisherige Kompetenz beizubehalten und in manchen Fällen in traditionellen Forschungsbereichen, basierend auf organischer Chemie, sogar zu verstärken.

Suggested Citation

  • Steven Casper & Catherine Matraves, 1997. "Corporate Governance and Firm Strategy in the Pharmaceutical Industry," CIG Working Papers FS IV 97-20, Wissenschaftszentrum Berlin (WZB), Research Unit: Competition and Innovation (CIG).
  • Handle: RePEc:wzb:wzebiv:fsiv97-20

    Download full text from publisher

    File URL:
    Download Restriction: no

    References listed on IDEAS

    1. Rebecca Henderson & Iain Cockburn, 1996. "Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery," RAND Journal of Economics, The RAND Corporation, vol. 27(1), pages 32-59, Spring.
    2. David J. TEECE, 2008. "Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy," World Scientific Book Chapters,in: The Transfer And Licensing Of Know-How And Intellectual Property Understanding the Multinational Enterprise in the Modern World, chapter 5, pages 67-87 World Scientific Publishing Co. Pte. Ltd..
    3. Henderson, Rebecca., 1994. "The evolution of integrative capability : innovation in cardiovascular drug discovery," Working papers 3711-94., Massachusetts Institute of Technology (MIT), Sloan School of Management.
    4. Joaquim Oliveira Martins & Stefano Scarpetta & Dirk Pilat, 1996. "Mark-Up Ratios in Manufacturing Industries: Estimates for 14 OECD Countries," OECD Economics Department Working Papers 162, OECD Publishing.
    5. DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G. & Lasagna, Louis, 1991. "Cost of innovation in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 10(2), pages 107-142, July.
    6. Vitols, Sigurt, 1995. "Corporate governance versus economic governance: banks and industrial restructuring in the US and Germany," Discussion Papers, Research Unit: Economic Change and Employment FS I 95-310, WZB Berlin Social Science Center.
    7. Masahiko Aoki, 2013. "Toward an Economic Model of the Japanese Firm," Chapters,in: Comparative Institutional Analysis, chapter 18, pages 315-341 Edward Elgar Publishing.
    8. Patel, Pari, 1995. "Localised Production of Technology for Global Markets," Cambridge Journal of Economics, Oxford University Press, vol. 19(1), pages 141-153, February.
    9. Mark Lehrer, 1997. "German Industrial Strategy in Turbulence: Corporate Governance and Managerial Hierarchies in Lufthansa," Industry and Innovation, Taylor & Francis Journals, vol. 4(1), pages 115-140.
    10. Iain Cockburn & Rebecca Henderson, 1997. "Public-Private Interaction and the Productivity of Pharmaceutical Research," NBER Working Papers 6018, National Bureau of Economic Research, Inc.
    11. Henry Grabowski & John Vernon, 1990. "A New Look at the Returns and Risks to Pharmaceutical R&D," Management Science, INFORMS, vol. 36(7), pages 804-821, July.
    12. Kenney, Martin, 1986. "Schumpeterian innovation and entrepreneurs in capitalism: A case study of the U.S. biotechnology industry," Research Policy, Elsevier, vol. 15(1), pages 21-31, February.
    13. Pavitt, Keith, 1991. "What makes basic research economically useful?," Research Policy, Elsevier, vol. 20(2), pages 109-119, April.
    14. Matraves, Catherine, 1999. "Market Structure, R&D and Advertising in the Pharmaceutical Industry," Journal of Industrial Economics, Wiley Blackwell, vol. 47(2), pages 169-194, June.
    15. repec:bla:stratm:v:15:y:1994:i:s1:p:63-84 is not listed on IDEAS
    16. Rebecca Henderson & Iain Cockburn, 1994. "Measuring Competence? Exploring Firm Effects in Pharmaceutical Research," Strategic Management Journal, Wiley Blackwell, vol. 15(S1), pages 63-84, December.
    Full references (including those not matched with items on IDEAS)


    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.

    Cited by:

    1. repec:ohe:monogr:000432 is not listed on IDEAS
    2. Nicola Lacetera, 2001. "Corporate Governance and the Governance of Innovation: The Case of Pharmaceutical Industry," Journal of Management & Governance, Springer;Accademia Italiana di Economia Aziendale (AIDEA), vol. 5(1), pages 29-59, March.
    3. Adleberger, Karen, 1999. "A Developmental German State? Explaining Growth in German Biotechnology and Venture Capital," UCAIS Berkeley Roundtable on the International Economy, Working Paper Series qt8z55s60f, UCAIS Berkeley Roundtable on the International Economy, UC Berkeley.
    4. Matraves, Catherine, 1999. "Market Structure, R&D and Advertising in the Pharmaceutical Industry," Journal of Industrial Economics, Wiley Blackwell, vol. 47(2), pages 169-194, June.


    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wzb:wzebiv:fsiv97-20. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Jennifer Rontganger). General contact details of provider: .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.